Profile data is unavailable for this security.
About the company
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
- Revenue in JPY (TTM)32.41bn
- Net income in JPY4.92bn
- Incorporated1973
- Employees1.44k
- LocationShin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
- Phone+81 355655001
- Fax+81 355656160
- Websitehttps://www.snbl.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chordia Therapeutics Inc | 0.00 | -2.00bn | 14.14bn | 22.00 | -- | 4.36 | -- | -- | -37.01 | -37.01 | 0.00 | 47.06 | 0.00 | -- | -- | 0.00 | -54.42 | -- | -57.62 | -- | -- | -- | -- | -- | -- | -642.98 | 0.00 | -- | -100.00 | -- | -918.09 | -- | -- | -- |
| 3-D Matrix Ltd | 6.93bn | -2.50bn | 19.96bn | 106.00 | -- | 9.01 | -- | 2.88 | -25.15 | -25.15 | 69.87 | 20.09 | 1.12 | 0.9378 | 4.48 | -- | -40.34 | -35.52 | -53.88 | -46.12 | 63.81 | 59.66 | -36.07 | -55.66 | 2.49 | -0.9616 | 0.5702 | -- | 51.11 | 59.47 | -878.94 | -- | -7.64 | -- |
| AnGes Inc | 699.31m | -27.55bn | 22.18bn | 55.00 | -- | 6.43 | -- | 31.72 | -102.39 | -102.39 | 2.65 | 9.65 | 0.0415 | 0.2713 | 8.19 | 12,714,800.00 | -163.47 | -42.57 | -191.95 | -49.90 | 33.22 | 27.35 | -3,939.97 | -7,043.23 | 1.34 | -- | 0.064 | -- | 320.72 | 14.52 | -278.20 | -- | 64.62 | -- |
| Pharma Foods International Co., Ltd. | 61.79bn | 226.00m | 23.70bn | 642.00 | 83.07 | 2.31 | 19.28 | 0.3835 | 9.81 | 9.81 | 2,165.52 | 352.38 | 1.78 | 1.93 | 13.99 | 96,250,780.00 | 0.6502 | 8.63 | 1.94 | 22.06 | 79.58 | 80.64 | 0.3657 | 4.13 | 0.777 | 8.23 | 0.5645 | 27.65 | -9.37 | 42.62 | 4.02 | 45.01 | 28.23 | -- |
| Healios KK | 588.00m | -4.37bn | 43.55bn | 65.00 | -- | 21.59 | -- | 74.06 | -46.81 | -46.81 | 6.42 | 19.27 | 0.0366 | -- | 2.63 | 9,046,154.00 | -27.16 | -24.31 | -43.03 | -30.77 | 73.30 | -- | -743.03 | -2,817.04 | -- | -1.59 | 0.7739 | -- | 362.81 | 44.46 | -10.78 | -- | 19.31 | -- |
| Shin Nippon Biomedical Laboratories Ltd | 32.41bn | 4.92bn | 58.20bn | 1.44k | 11.82 | 1.45 | 7.79 | 1.80 | 118.30 | 118.30 | 778.58 | 961.35 | 0.3842 | 1.24 | 5.30 | 22,572,290.00 | 5.77 | 9.90 | 8.40 | 14.82 | 52.33 | 52.68 | 15.01 | 23.35 | 0.6946 | -- | 0.4633 | 30.49 | 22.55 | 17.36 | -10.96 | 14.07 | 54.79 | 58.49 |
| Heartseed Inc | 2.64bn | 614.54m | 61.21bn | 39.00 | 102.04 | 8.13 | 165.68 | 23.19 | 26.58 | 26.58 | 117.83 | 333.72 | 0.4047 | -- | 9.60 | 67,685,900.00 | 9.42 | -- | 9.89 | -- | -- | -- | 23.28 | -- | 19.27 | 157.48 | 0.0004 | -- | 153.42 | -- | 44.84 | -- | -- | -- |
| Takara Bio Inc | 45.04bn | 1.04bn | 96.81bn | 1.78k | 93.00 | 0.8382 | 17.97 | 2.15 | 8.65 | 8.65 | 374.03 | 959.19 | 0.3653 | 1.56 | 3.57 | 25,317,030.00 | 0.8816 | 8.66 | 0.9384 | 9.70 | 57.88 | 63.76 | 2.41 | 17.16 | 6.34 | -- | 0.0094 | 31.40 | 3.53 | 5.44 | -29.59 | -22.88 | 20.46 | 16.27 |
| SanBio Co Ltd | 0.00 | -4.27bn | 156.56bn | 29.00 | -- | 82.62 | -- | -- | -61.10 | -61.10 | 0.00 | 26.31 | 0.00 | -- | -- | 0.00 | -98.97 | -47.32 | -112.89 | -57.01 | -- | -- | -- | -- | -- | -4.45 | 0.4276 | -- | -- | -- | -9.02 | -- | -46.04 | -- |
| GNI Group Ltd | 22.98bn | -886.60m | 158.44bn | 867.00 | -- | 4.62 | -- | 6.89 | -17.71 | -17.71 | 458.85 | 679.05 | 0.3441 | 2.05 | 4.58 | 26,509,560.00 | -3.92 | 5.12 | -4.98 | 6.23 | 75.80 | 83.27 | -11.40 | 11.23 | 1.96 | -2.14 | 0.153 | 0.00 | -9.22 | 25.96 | -86.43 | 43.28 | 20.19 | -- |
| Peptidream Inc | 46.68bn | 14.82bn | 204.77bn | 621.00 | 13.80 | 3.71 | 12.05 | 4.39 | 114.17 | 114.17 | 360.07 | 424.19 | 0.6209 | 4.28 | 9.90 | 75,176,500.00 | 19.72 | 13.49 | 22.55 | 15.79 | 73.89 | 70.05 | 31.75 | 26.45 | 4.78 | 72.92 | 0.2574 | 0.00 | 62.57 | -- | 394.59 | -- | -- | -- |
Data as of Jul 04 2025. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY
11.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sumitomo Mitsui DS Asset Management Co., Ltd.as of 05 Jun 2025 | 946.00k | 2.27% |
| Nomura Asset Management Co., Ltd.as of 05 Jun 2025 | 864.70k | 2.08% |
| The Vanguard Group, Inc.as of 04 Jun 2025 | 676.43k | 1.63% |
| Asset Management One Co., Ltd.as of 05 Jun 2025 | 652.50k | 1.57% |
| Daiwa Asset Management Co. Ltd.as of 30 May 2025 | 405.60k | 0.97% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 373.20k | 0.90% |
| Nikko Asset Management Co., Ltd.as of 06 Jun 2025 | 316.50k | 0.76% |
| Dimensional Fund Advisors LPas of 05 Jun 2025 | 281.40k | 0.68% |
| Mellon Investments Corp.as of 06 Jun 2025 | 165.10k | 0.40% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jun 2025 | 163.40k | 0.39% |
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
